Tags

Type your tag names separated by a space and hit enter

Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study.
Endocr Relat Cancer. 2012 Aug; 19(4):473-83.ER

Abstract

The study aims to examine whether the annual variations in fasting plasma glucose (FPG) measurements, represented by the coefficient of variation (CV), predict cancer incidence and mortality in the subsequent years independent of traditional risk factors of type 2 diabetic patients. A computerized database of patients with type 2 diabetes of 30 years old and older (n=4805) enrolled in the Diabetes Care Management Program of a medical center before 2006 was analyzed using a time-dependent Cox's proportional hazards regression model. The mortality rates for the first, second, and third tertiles of the first annual FPG-CV were 8.64, 12.71, and 30.82 per 1000 person-years respectively. After adjusting for mean FPG, HbA1c, and other risk factors, the annual FPG-CV was independently associated with cancer incidence, cancer mortality, and cancer incidence or mortality, and the corresponding hazard ratios for the third vs first tertile of the annual FPG-CV were 3.03 (1.98, 4.65), 5.04 (2.32, 10.94), and 2.86 (1.91, 4.29) respectively. The annual variation in FPG was a strong predictor of cancer incidence and mortality in type 2 diabetic patients; therefore, glucose variation may be important in the clinical practice of care management and cancer prevention.

Authors+Show Affiliations

School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22544890

Citation

Lin, Cheng-Chieh, et al. "Annual Fasting Plasma Glucose Variation Increases Risk of Cancer Incidence and Mortality in Patients With Type 2 Diabetes: the Taichung Diabetes Study." Endocrine-related Cancer, vol. 19, no. 4, 2012, pp. 473-83.
Lin CC, Li CI, Liu CS, et al. Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study. Endocr Relat Cancer. 2012;19(4):473-83.
Lin, C. C., Li, C. I., Liu, C. S., Lin, W. Y., Chen, C. C., Yang, S. Y., Lee, C. C., & Li, T. C. (2012). Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study. Endocrine-related Cancer, 19(4), 473-83. https://doi.org/10.1530/ERC-12-0038
Lin CC, et al. Annual Fasting Plasma Glucose Variation Increases Risk of Cancer Incidence and Mortality in Patients With Type 2 Diabetes: the Taichung Diabetes Study. Endocr Relat Cancer. 2012;19(4):473-83. PubMed PMID: 22544890.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study. AU - Lin,Cheng-Chieh, AU - Li,Chia-Ing, AU - Liu,Chiu-Shong, AU - Lin,Wen-Yuan, AU - Chen,Ching-Chu, AU - Yang,Sing-Yu, AU - Lee,Cheng-Chun, AU - Li,Tsai-Chung, Y1 - 2012/07/18/ PY - 2012/5/1/entrez PY - 2012/5/1/pubmed PY - 2012/11/14/medline SP - 473 EP - 83 JF - Endocrine-related cancer JO - Endocr Relat Cancer VL - 19 IS - 4 N2 - The study aims to examine whether the annual variations in fasting plasma glucose (FPG) measurements, represented by the coefficient of variation (CV), predict cancer incidence and mortality in the subsequent years independent of traditional risk factors of type 2 diabetic patients. A computerized database of patients with type 2 diabetes of 30 years old and older (n=4805) enrolled in the Diabetes Care Management Program of a medical center before 2006 was analyzed using a time-dependent Cox's proportional hazards regression model. The mortality rates for the first, second, and third tertiles of the first annual FPG-CV were 8.64, 12.71, and 30.82 per 1000 person-years respectively. After adjusting for mean FPG, HbA1c, and other risk factors, the annual FPG-CV was independently associated with cancer incidence, cancer mortality, and cancer incidence or mortality, and the corresponding hazard ratios for the third vs first tertile of the annual FPG-CV were 3.03 (1.98, 4.65), 5.04 (2.32, 10.94), and 2.86 (1.91, 4.29) respectively. The annual variation in FPG was a strong predictor of cancer incidence and mortality in type 2 diabetic patients; therefore, glucose variation may be important in the clinical practice of care management and cancer prevention. SN - 1479-6821 UR - https://www.unboundmedicine.com/medline/citation/22544890/Annual_fasting_plasma_glucose_variation_increases_risk_of_cancer_incidence_and_mortality_in_patients_with_type_2_diabetes:_the_Taichung_Diabetes_Study_ L2 - https://erc.bioscientifica.com/doi/10.1530/ERC-12-0038 DB - PRIME DP - Unbound Medicine ER -